PubRank

Marjolein van Ballegooijen

Author PubWeight™ 117.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012 16.55
2 Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010 13.27
3 Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008 6.99
4 Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2011 5.72
5 Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008 4.77
6 Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010 3.05
7 POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004 2.89
8 How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006 2.68
9 Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev 2012 2.39
10 Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009 2.35
11 Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 2014 2.31
12 Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012 2.05
13 Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009 1.96
14 Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009 1.89
15 At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer 2009 1.88
16 Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ 2009 1.81
17 A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011 1.77
18 Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012 1.71
19 Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 2011 1.66
20 Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006 1.45
21 Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health 2011 1.44
22 A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer 2009 1.37
23 Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007 1.37
24 Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 2008 1.36
25 Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011 1.33
26 Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 2014 1.32
27 Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007 1.30
28 Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002 1.24
29 Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010 1.24
30 Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2012 1.14
31 Girls' preferences for HPV vaccination: a discrete choice experiment. Vaccine 2010 1.11
32 Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2010 1.11
33 Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial. BMC Gastroenterol 2010 1.10
34 Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol 2011 1.07
35 Features of adenoma and colonoscopy associated with recurrent colorectal neoplasia based on a large community-based study. Gastroenterology 2013 1.01
36 Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2013 1.00
37 Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2012 0.96
38 Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005 0.94
39 How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 2011 0.93
40 Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies. Int J Cancer 2007 0.93
41 Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. Histopathology 2011 0.93
42 Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer. Cancer Epidemiol 2013 0.92
43 Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis. Cancer Causes Control 2010 0.92
44 Process performance of cervical screening programmes in Europe. Eur J Cancer 2009 0.92
45 A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programs. Am J Gastroenterol 2010 0.91
46 Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 2011 0.89
47 Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer 2011 0.85
48 Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int J Cancer 2009 0.85
49 Parental decisional strategies regarding HPV vaccination before media debates: a focus group study. J Health Commun 2013 0.84
50 Anxiety and borderline PAP smear results. Eur J Cancer 2010 0.84
51 Informed choice on Pap smear still limited by lack of knowledge on the meaning of false-positive or false-negative test results. Patient Educ Couns 2011 0.83
52 No increased risk for cervical cancer after a broader definition of a negative Pap smear. Int J Cancer 2008 0.83
53 Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer 2011 0.82
54 Increasing girls' knowledge about human papillomavirus vaccination with a pre-test and a national leaflet: a quasi-experimental study. BMC Public Health 2013 0.81
55 Does lowering the screening age for cervical cancer in The Netherlands make sense? Int J Cancer 2008 0.80
56 Parents' preferences for vaccinating daughters against human papillomavirus in the Netherlands: a discrete choice experiment. BMC Public Health 2014 0.79
57 Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making 2012 0.79
58 How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age? Int J Cancer 2013 0.78
59 Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 2011 0.78
60 United States Preventive Services Task Force recommendations: age to end screening misunderstood. Dis Colon Rectum 2010 0.78
61 Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis. Cancer Causes Control 2012 0.77
62 Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study. Cancer Causes Control 2014 0.77
63 Effects of streamlining cervical cancer screening the Dutch way: consequences of changes in the Dutch KOPAC-based follow-up protocol and consensus-based limitation of equivocal cytology. Acta Cytol 2011 0.76
64 Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Med Care 2015 0.76
65 Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: a questionnaire study. Eur J Cancer 2008 0.76
66 Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs. J Clin Epidemiol 2002 0.75